Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Capex-to-Operating-Cash-Flow Related Terms
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Capex-to-Operating-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Capex-to-Operating-Cash-Flow Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
CAS:PRO vs ZTS, UTHR, VTRS: Capex-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Capex-to-Operating-Cash-Flow vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.35 mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Capex-to-Operating-Cash-Flow of 0.35 as of Dec. 2025. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #999999 out of 552 companies in the Drug Manufacturers industry.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Capex-to-Operating-Cash-Flow too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Capex-to-Operating-Cash-Flow is 0.35. The Drug Manufacturers industry median Capex-to-Operating-Cash-Flow is 0.36. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 0.35 is 2.8% below this industry median. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #999999 out of 552 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Capex-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #999999 out of 552 companies for Capex-to-Operating-Cash-Flow. This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.36. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 0.35 is 2.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Capex-to-Operating-Cash-Flow among Drug Manufacturers companies is 0.36, based on 552 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Capex-to-Operating-Cash-Flow of 0.35 is 2.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Cash-Flow is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Capex-to-Operating-Cash-Flow is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,362.89, compared to a current price of MAD1,480.00 — trading 8.6% above its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.35 and 2.8% below the Drug Manufacturers industry median of 0.36. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Capex-to-Operating-Cash-Flow is 0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,480.00 is trading 8.6% above its estimated GF Value™ of MAD1,362.89.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
Capex-to-Operating-Cash-Flow: 0.35
GF Value™: MAD1,362.89 vs. price of MAD1,480.00 (8.6% above fair value)
Industry Position: 2.8% below the Drug Manufacturers median (#999999 of 552)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
76GF Score
Get the complete analysis for CAS:PRO
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
